NAD(P)H:quinone oxidoreductase1 (DT-diaphorase) expression in normal and tumor tissues.
NAD(P)H:Quinone Oxidoreductase1 (NQO1) also known as DT-diaphorase is a flavoprotein that catalyzes the two-electron reduction of quinones, quinone imines and azo-dyes and thereby protects cells against mutagenicity and carcinogenicity resulting from free radicals and toxic oxygen metabolites generated by the one-electron reductions catalyzed by cytochromes P450 and other enzymes. High levels of NQO1 gene expression have been observed in liver, lung, colon and breast tumors as compared to normal tissues of the same origin. The transcription of the NQO1 gene is activated in response to exposure to bifunctional (e.g. beta-naphthoflavone (beta-NF), 2, 3, 7, 8 tetrachorodibenzo-p-dioxin (TCDD)) and monofunctional (phenolic antioxidants/chemoprotectors e.g. 2(3)-tert-butyl-4-hydroxy-anisole (BHA)) inducers. The high level of expression of the NQO1 gene and its induction by beta-NF and BHA require the presence of an AP1 binding site contained within the human Antioxidant Response Element (hARE) and are mediated by products of proto-oncogenes, Jun and Fos. Induction of NQO1 gene expression involves transfer of a redox signal from xenobiotics to unknown 'redox protein(s)' which in turn, modify the Jun and Fos proteins for greater affinity towards the AP1 site of the NQO1 gene and activates transcription. The expression and regulation of the NQO1 gene is complex as many additional cis-elements have been identified in the promoter region and is a subject of great future interest. In addition to established tumors, NQO1 gene expression is also increased in developing tumors, indicating a role in cellular defense during tumorigenesis. It has been proposed that low molecular weight substance(s) can diffuse from tumor cells into surrounding normal cells and activate the expression of the NQO1 gene. Purification and characterization of such substance(s) may provide important information in regard to the mechanism of activation of NQO1 gene expression and the role of increased NQO1 expression in tumor development. In view of the general consensus that NQO1 is over-expressed in tumor cells and the realization that NQO1 may either activate or detoxify xenobiotics, it is important to establish the role of NQO1 in the activation, and the detoxification of xenobiotics and drugs and in the intrinsic sensitivity of tumors to bioreductive alkylating aziridinyl benzoquinones such as diaziquone (AZQ), mitomycin C (MMC), and indoloquinone EO9, as well as to the dinitrophenyl aziridine, CB1954, and the benzotriazine-di-N-oxide, SR 4233.
Dept. of Pharmacology, Fox Chase Cancer Center, Philadelphia, PA 19111.
M
M
Belinsky
A K
AK
Jaiswal
D000818:Animals; D000970:Antineoplastic Agents / Q000627:therapeutic use; D001483:Base Sequence; D001940:Breast / Q000201:enzymology; D001943:Breast Neoplasms / Q000201:enzymology; D003106:Colon / Q000201:enzymology; D003110:Colonic Neoplasms / Q000201:enzymology; D004790:Enzyme Induction / Q000187:drug effects; D005260:Female; D015870:Gene Expression; D006801:Humans; D008099:Liver / Q000201:enzymology; D008113:Liver Neoplasms / Q000201:enzymology; D008168:Lung / Q000201:enzymology; D008175:Lung Neoplasms / Q000201:enzymology; D008969:Molecular Sequence Data; D016660:NAD(P)H Dehydrogenase (Quinone) / Q000096:biosynthesis*; D009369:Neoplasms / Q000188:drug therapy / Q000201:enzymology*; D009374:Neoplasms, Experimental / Q000188:drug therapy / Q000201:enzymology; D009838:Oligodeoxyribonucleotides; D011809:Quinones / Q000378:metabolism; D012016:Reference Values; D015262:Xenobiotics / Q000494:pharmacology
D000970:Antineoplastic Agents; D009838:Oligodeoxyribonucleotides; D011809:Quinones; D015262:Xenobiotics; D016660:NAD(P)H Dehydrogenase (Quinone)